Shopping Cart 0
Cart Subtotal
USD 0

Polycystic-Ovarian-Syndrome-Pipeline-Review-H2-2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Polycystic Ovarian Syndrome-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome-Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Polycystic Ovarian Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome (Women's Health).

The pipeline guide reviews pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Polycystic Ovarian Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Polycystic Ovarian Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Polycystic Ovarian Syndrome (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Ovarian Syndrome-Overview

Polycystic Ovarian Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Ovarian Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Ovarian Syndrome-Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Bayer AG

Crinetics Pharmaceuticals Inc

EffRx Pharmaceuticals SA

Millendo Therapeutics Inc

Novartis AG

Ogeda SA

Vicore Pharma AB

Polycystic Ovarian Syndrome-Drug Profiles

BAY-1161116-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-21-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDSCR-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDT-501-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LIK-066-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metformin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MLE-4901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycystic Ovarian Syndrome-Dormant Projects

Polycystic Ovarian Syndrome-Discontinued Products

Polycystic Ovarian Syndrome-Product Development Milestones

Featured News & Press Releases

Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for MLE4901 at ENDO 2017 and Kisspeptin 2017

Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364

Nov 03, 2016: Millendo Therapeutics Announces Data Presentations at Androgen Excess and Polycystic Ovary Syndrome Society Annual Meeting

Nov 02, 2016: Millendo Therapeutics to present data on MLE-4901 program at Society for Endocrinology British Endocrine Societies Conference

Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome

Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials

Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients

Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364

Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting

Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome

Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364

Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Pediatric Populations

Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Addex Therapeutics Ltd, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Bayer AG, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Polycystic Ovarian Syndrome-Pipeline by EffRx Pharmaceuticals SA, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Millendo Therapeutics Inc, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Novartis AG, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Ogeda SA, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Vicore Pharma AB, H2 2017

Polycystic Ovarian Syndrome-Dormant Projects, H2 2017

Polycystic Ovarian Syndrome-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Polycystic Ovarian Syndrome Therapeutic Products under Development, Key Players in Polycystic Ovarian Syndrome Therapeutics, Polycystic Ovarian Syndrome Pipeline Overview, Polycystic Ovarian Syndrome Pipeline, Polycystic Ovarian Syndrome Pipeline Assessment


Companies

Addex Therapeutics Ltd

Bayer AG

Crinetics Pharmaceuticals Inc

EffRx Pharmaceuticals SA

Millendo Therapeutics Inc

Novartis AG

Ogeda SA

Vicore Pharma AB

Polycystic Ovarian Syndrome-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome-Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Polycystic Ovarian Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome (Women's Health).

The pipeline guide reviews pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Polycystic Ovarian Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Polycystic Ovarian Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Polycystic Ovarian Syndrome (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Ovarian Syndrome-Overview

Polycystic Ovarian Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Ovarian Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Ovarian Syndrome-Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Bayer AG

Crinetics Pharmaceuticals Inc

EffRx Pharmaceuticals SA

Millendo Therapeutics Inc

Novartis AG

Ogeda SA

Vicore Pharma AB

Polycystic Ovarian Syndrome-Drug Profiles

BAY-1161116-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-21-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDSCR-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDT-501-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LIK-066-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metformin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MLE-4901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycystic Ovarian Syndrome-Dormant Projects

Polycystic Ovarian Syndrome-Discontinued Products

Polycystic Ovarian Syndrome-Product Development Milestones

Featured News & Press Releases

Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for MLE4901 at ENDO 2017 and Kisspeptin 2017

Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364

Nov 03, 2016: Millendo Therapeutics Announces Data Presentations at Androgen Excess and Polycystic Ovary Syndrome Society Annual Meeting

Nov 02, 2016: Millendo Therapeutics to present data on MLE-4901 program at Society for Endocrinology British Endocrine Societies Conference

Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome

Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials

Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients

Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364

Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting

Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome

Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364

Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Pediatric Populations

Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Polycystic Ovarian Syndrome, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Addex Therapeutics Ltd, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Bayer AG, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Polycystic Ovarian Syndrome-Pipeline by EffRx Pharmaceuticals SA, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Millendo Therapeutics Inc, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Novartis AG, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Ogeda SA, H2 2017

Polycystic Ovarian Syndrome-Pipeline by Vicore Pharma AB, H2 2017

Polycystic Ovarian Syndrome-Dormant Projects, H2 2017

Polycystic Ovarian Syndrome-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Polycystic Ovarian Syndrome Therapeutic Products under Development, Key Players in Polycystic Ovarian Syndrome Therapeutics, Polycystic Ovarian Syndrome Pipeline Overview, Polycystic Ovarian Syndrome Pipeline, Polycystic Ovarian Syndrome Pipeline Assessment


Companies

Addex Therapeutics Ltd

Bayer AG

Crinetics Pharmaceuticals Inc

EffRx Pharmaceuticals SA

Millendo Therapeutics Inc

Novartis AG

Ogeda SA

Vicore Pharma AB